VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31

vTv Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$26.94+0.40 (+1.51%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

vTv Therapeutics Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	0	1.02	0	2.02	4.01	6.41	2.76	12	0.29	0.63	0.52	1.55	0.98
Research & Development	18	12	14	12	13	11	15	23	40	45	27	17	22
General & Administrative	15	14	12	12	12	7.25	8.54	9.22	11	9.91	9.08	12	11
Operating Expenses	33	25	26	25	26	18	24	32	51	56	39	30	37
Operating Income	-33	-24	-26	-23	-22	-12	-21	-20	-51	-55	-38	-29	-36
Interest Expense	–	0	0.01	0.02	0.01	0.69	1.83	3.29	3.09	0.40	0.11	0.29	0.48
Interest & Investment Income	1.87	1.57	0.47	0.35	0.00	0.01	0.05	0.06	0.12	0.09	0.04	0.00	–
Other Non-Operating Income	–	–	-1.50	-3.62	2.45	0	0.00	0.05	–	-0.02	-0.84	-0.50	0.04
Merger & Restructuring Charges	–	–	–	–	1.60	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0.10	0	0	–	–	–
Gain (Loss) on Sale of Assets	-0.01	0	0	–	–	–	0.29	0.01	0.01	0.00	0.01	-0.03	-0.02
Pretax Income	-31	-23	-26	-25	-18	-13	-22	-24	-54	-55	-41	-36	-48
Income Tax Expense	0	0.10	0	0.20	0.12	0	0.10	0.20	0.80	0	0	0	–
Net Income incl. Noncontrolling Interests	-31	-23	-26	-25	-18	-13	-22	-24	-55	-55	-41	-36	-48
Minority Interest in Earnings	-4.11	-4.24	-5.72	-5.91	-4.74	-4.30	-8.89	-16	-39	-39	-14	–	–
Net Income	-27	-18	-20	-19	-13	-8.50	-13	-7.91	-16	-16	-27	-36	-48
Net Income to Common	-27	-18	-20	-19	-13	-8.50	-18	-8.65	-16	-16	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -25.1%
Net margin: -12.9%
Return on equity, FY2025: -70.4%

Financial strength

Current ratio: 12.48
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1234.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –